GDF5 has been shown to have neuroprotective effects in rat models of PD, specifically in 6-hydroxydopamine (6-OHDA) lesion models [18, 19], and more recently in the AAV-α-synuclein model [14]. Here, SNCA is linked to Parkinson disease.